Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease

Cardiovascular Therapeutics

Volumn 30, Issue 5, 2012, Pages 277-286

  Wustmann, Kerstin ^a   Klaey, Marco ^a   Burow, Annika ^a   Shaw, Sidney G ^b   Hess, Otto M ^a   Allemann, Yves ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cardiovascular disease; Endothelial function; Flow mediated dilation; Folic acid; Rosuvastatin; Vitamin B6 and B12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; HYPOCHOLESTEROLEMIC AGENT; PYRIDOXINE; ROSUVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; VASODILATATION; VITAMIN SUPPLEMENTATION;

AGED; ANTICHOLESTEREMIC AGENTS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ENDOTHELIUM; ENDPOINT DETERMINATION; FEMALE; FLUOROBENZENES; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PYRIMIDINES; SULFONAMIDES; VASODILATION; VITAMIN B COMPLEX; VITAMINS;

EID: 84866050088     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00272.x     Document Type: Article

References (35)

1. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-1474.
2. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: The framingham heart study. Circulation 2004;109:613-619.
3. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002;39:257-265.
4. Gokce N, Keaney JF, Jr., Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-1775.
5. Patti G, Pasceri V, Melfi R, et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 2005;111:70-75.
6. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. Jama 1997;277:1775-1781.
7. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
8. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and b vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008;299:2027-2036.
9. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and b vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
10. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
11. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral b vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:2479-2483.
12. Mangoni AA, Sherwood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 2005;18:220-226.
13. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin b12, and vitamin b6 on clinical outcome after percutaneous coronary intervention: The swiss heart study: A randomized controlled trial. Jama 2002;288:973-979.
14. Sydow K, Schwedhelm E, Arakawa N, et al. Adma and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: Effects of l-arginine and b vitamins. Cardiovasc Res 2003;57:244-252.
15. Title LM, Cummings PM, Giddens K, Genest JJ, Jr., Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36:758-765.
16. Woo KS, Chook P, Chan LL, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am J Med 2002;112:535-539.
17. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: From folate fortification to the recent clinical trials. Eur Heart J 2009;30:6-15.
18. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-26.
19. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-1500.
20. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005;149:473.
21. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004;95:217-223.
22. Vita JA, Gokce N, Duffy SJ, et al. Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease. Am J Cardiol 2003;91:857-860.
23. Gounari P, Tousoulis D, Antoniades C, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol 2010;142:87-91.
24. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-2363.
25. Leung WH, Lau CP, Wong CK.Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. The Lancet 1993;341:1496-1500.
26. Ray KK, Cannon CP.The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:1425-1433.
27. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008;359:2195-2207.
28. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002;942:23-30.
29. Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of nf-kappab through an increased production of intracellular reactive oxygen species. J Biol Chem 2000;275:12633-12638.
30. Cominacini L, Anselmi M, Garbin U, et al. Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa b activation in patients with unstable angina. J Am Coll Cardiol 2005;46:799-806.
31. Shirodaria C, Antoniades C, Lee J, et al. Global improvement of vascular function and redox state with low-dose folic acid: Implications for folate therapy in patients with coronary artery disease. Circulation 2007;115:2262-2270.
32. Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006;114:1193-1201.
33. Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA.Folic acid improves endothelial dysfunction in type 2 diabetes-an effect independent of homocysteine-lowering. Vasc Med 2006;11:101-109.
34. Ferretti G, Bacchetti T, Moroni C, Vignini A, Nanetti L, Curatola G.Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 2004;92:351-360.
35. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998;141:1-15.